Novartis

Swiss pharmaceutical company Novartis has struck a deal worth up to $7.8 billion with China's Abogen Biosciences covering mRNA-based therapies, according to Reuters. The agreement highlights growing Western interest in Chinese biotech and in mRNA platforms beyond vaccines. Analysts are likely to weigh what the deal means for Novartis's pipeline and for China's expanding life sciences sector.

Novartis has agreed to acquire Chinese biotech Abogen in a deal worth $7.8bn, betting on bispecific T-cell engagers (BiTEs) aimed at autoimmune diseases. The move signals the Swiss drugmaker's push into next-generation immunology therapies, expanding its pipeline beyond traditional treatments. Industry watchers see it as part of a broader wave of big pharma deals targeting autoimmune conditions with engineered antibody technologies.

Swiss drugmaker Novartis has agreed a deal worth about $7.8 billion with China's Abogen Biosciences, according to Reuters. The agreement centres on mRNA technology, marking a significant move by Novartis into the field and a landmark licensing arrangement for a Chinese biotech firm with a major Western pharmaceutical partner.